S&P 500   3,148.59 (+1.00%)
DOW   27,999.53 (+1.16%)
QQQ   204.77 (+1.16%)
AAPL   269.49 (+1.47%)
FB   201.25 (+0.94%)
MSFT   151.18 (+0.83%)
GOOGL   1,338.74 (+1.50%)
AMZN   1,745.75 (-0.85%)
CGC   18.51 (-0.48%)
NVDA   212.99 (+1.70%)
MU   48.02 (+3.00%)
BABA   200.16 (+0.08%)
GE   11.01 (+2.04%)
TSLA   337.78 (+1.43%)
T   38.41 (+0.58%)
AMD   39.86 (+0.43%)
ACB   2.43 (-0.82%)
F   9.00 (+0.67%)
PRI   136.22 (+1.43%)
NFLX   304.71 (+0.13%)
BAC   33.75 (+1.99%)
GILD   67.07 (+0.48%)
DIS   147.97 (+0.36%)
S&P 500   3,148.59 (+1.00%)
DOW   27,999.53 (+1.16%)
QQQ   204.77 (+1.16%)
AAPL   269.49 (+1.47%)
FB   201.25 (+0.94%)
MSFT   151.18 (+0.83%)
GOOGL   1,338.74 (+1.50%)
AMZN   1,745.75 (-0.85%)
CGC   18.51 (-0.48%)
NVDA   212.99 (+1.70%)
MU   48.02 (+3.00%)
BABA   200.16 (+0.08%)
GE   11.01 (+2.04%)
TSLA   337.78 (+1.43%)
T   38.41 (+0.58%)
AMD   39.86 (+0.43%)
ACB   2.43 (-0.82%)
F   9.00 (+0.67%)
PRI   136.22 (+1.43%)
NFLX   304.71 (+0.13%)
BAC   33.75 (+1.99%)
GILD   67.07 (+0.48%)
DIS   147.97 (+0.36%)
S&P 500   3,148.59 (+1.00%)
DOW   27,999.53 (+1.16%)
QQQ   204.77 (+1.16%)
AAPL   269.49 (+1.47%)
FB   201.25 (+0.94%)
MSFT   151.18 (+0.83%)
GOOGL   1,338.74 (+1.50%)
AMZN   1,745.75 (-0.85%)
CGC   18.51 (-0.48%)
NVDA   212.99 (+1.70%)
MU   48.02 (+3.00%)
BABA   200.16 (+0.08%)
GE   11.01 (+2.04%)
TSLA   337.78 (+1.43%)
T   38.41 (+0.58%)
AMD   39.86 (+0.43%)
ACB   2.43 (-0.82%)
F   9.00 (+0.67%)
PRI   136.22 (+1.43%)
NFLX   304.71 (+0.13%)
BAC   33.75 (+1.99%)
GILD   67.07 (+0.48%)
DIS   147.97 (+0.36%)
S&P 500   3,148.59 (+1.00%)
DOW   27,999.53 (+1.16%)
QQQ   204.77 (+1.16%)
AAPL   269.49 (+1.47%)
FB   201.25 (+0.94%)
MSFT   151.18 (+0.83%)
GOOGL   1,338.74 (+1.50%)
AMZN   1,745.75 (-0.85%)
CGC   18.51 (-0.48%)
NVDA   212.99 (+1.70%)
MU   48.02 (+3.00%)
BABA   200.16 (+0.08%)
GE   11.01 (+2.04%)
TSLA   337.78 (+1.43%)
T   38.41 (+0.58%)
AMD   39.86 (+0.43%)
ACB   2.43 (-0.82%)
F   9.00 (+0.67%)
PRI   136.22 (+1.43%)
NFLX   304.71 (+0.13%)
BAC   33.75 (+1.99%)
GILD   67.07 (+0.48%)
DIS   147.97 (+0.36%)
Log in

NASDAQ:AVRO - Avrobio Stock Price, Forecast & News

$18.02
+0.25 (+1.41 %)
(As of 12/6/2019 11:25 AM ET)
Today's Range
$17.79
Now: $18.02
$18.02
50-Day Range
$13.10
MA: $14.89
$17.80
52-Week Range
$11.85
Now: $18.02
$28.52
Volume150 shs
Average Volume224,171 shs
Market Capitalization$570.64 million
P/E RatioN/A
Dividend YieldN/A
Beta2.66
AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AVRO
CUSIPN/A
CIKN/A
Phone617-914-8420

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.10 per share

Profitability

Net Income$-46,360,000.00

Miscellaneous

Employees49
Market Cap$570.64 million
Next Earnings Date3/23/2020 (Estimated)
OptionableNot Optionable

Receive AVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVRO and its competitors with MarketBeat's FREE daily newsletter.


Avrobio (NASDAQ:AVRO) Frequently Asked Questions

What is Avrobio's stock symbol?

Avrobio trades on the NASDAQ under the ticker symbol "AVRO."

How were Avrobio's earnings last quarter?

Avrobio Inc (NASDAQ:AVRO) released its quarterly earnings results on Thursday, November, 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.59) by $0.02. View Avrobio's Earnings History.

When is Avrobio's next earnings date?

Avrobio is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for Avrobio.

What price target have analysts set for AVRO?

7 brokerages have issued twelve-month target prices for Avrobio's stock. Their forecasts range from $19.00 to $43.00. On average, they anticipate Avrobio's stock price to reach $30.74 in the next twelve months. This suggests a possible upside of 72.8% from the stock's current price. View Analyst Price Targets for Avrobio.

What is the consensus analysts' recommendation for Avrobio?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avrobio in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avrobio.

Has Avrobio been receiving favorable news coverage?

Media coverage about AVRO stock has been trending extremely negative on Friday, InfoTrie reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Avrobio earned a daily sentiment score of -5.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Avrobio.

Are investors shorting Avrobio?

Avrobio saw a decline in short interest during the month of October. As of October 15th, there was short interest totalling 1,070,000 shares, a decline of 25.2% from the September 15th total of 1,430,000 shares. Based on an average trading volume of 241,100 shares, the days-to-cover ratio is currently 4.4 days. Approximately 4.7% of the shares of the company are short sold. View Avrobio's Current Options Chain.

Who are some of Avrobio's key competitors?

What other stocks do shareholders of Avrobio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avrobio investors own include Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), BIOLINERX LTD/S (BLRX), bluebird bio (BLUE), Audentes Therapeutics (BOLD), Celgene (CELG), DexCom (DXCM), Exelixis (EXEL), Fate Therapeutics (FATE) and Uniqure (QURE).

Who are Avrobio's key executives?

Avrobio's management team includes the folowing people:
  • Mr. Geoff MacKay, Co- Founder, Pres, CEO & Director (Age 53)
  • Mr. Steven N. Avruch, VP, Gen. Counsel & Sec. (Age 58)
  • Mr. Jeffrey Medin Ph.D., Scientific Founder
  • Mr. Erik Ostrowski, CFO & Treasurer (Age 46)
  • Dr. Kim Warren, Head of Operations

When did Avrobio IPO?

(AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.

Who are Avrobio's major shareholders?

Avrobio's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Eventide Asset Management LLC (4.12%), Tang Capital Management LLC (2.62%), Emerald Advisers LLC (2.73%), State Street Corp (2.04%), Emerald Mutual Fund Advisers Trust (2.66%) and Orbimed Advisors LLC (1.80%). Company insiders that own Avrobio stock include Bruce Booth, Christopher Paige and Geoffrey Mackay. View Institutional Ownership Trends for Avrobio.

Which major investors are selling Avrobio stock?

AVRO stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. Company insiders that have sold Avrobio company stock in the last year include Christopher Paige and Geoffrey Mackay. View Insider Buying and Selling for Avrobio.

Which major investors are buying Avrobio stock?

AVRO stock was purchased by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Orbimed Advisors LLC, State Street Corp, Eventide Asset Management LLC, Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Squarepoint Ops LLC and California State Teachers Retirement System. View Insider Buying and Selling for Avrobio.

How do I buy shares of Avrobio?

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Avrobio's stock price today?

One share of AVRO stock can currently be purchased for approximately $17.79.

How big of a company is Avrobio?

Avrobio has a market capitalization of $563.36 million. The company earns $-46,360,000.00 in net income (profit) each year or ($3.62) on an earnings per share basis. Avrobio employs 49 workers across the globe.View Additional Information About Avrobio.

What is Avrobio's official website?

The official website for Avrobio is http://www.avrobio.com/.

How can I contact Avrobio?

Avrobio's mailing address is ONE KENDALL SQUARE BLDG. 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]


MarketBeat Community Rating for Avrobio (NASDAQ AVRO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  119 (Vote Outperform)
Underperform Votes:  87 (Vote Underperform)
Total Votes:  206
MarketBeat's community ratings are surveys of what our community members think about Avrobio and other stocks. Vote "Outperform" if you believe AVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel